Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 4/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL804896 | 0.91 | CCR2 (0.43) | CCR2MAPTTACR1GAA | |
| SCHEMBL799313 | 0.83 | — | — | |
| SCHEMBL12626813 | 0.82 | SERPINE1 (0.41) | CCR2MAPTCACNA1HCACNA1BTACR1 | |
| SCHEMBL799312 | 0.80 | CA12 (0.44) | CCR2MAPTNOS1NOS2CACNA1H | |
| SCHEMBL14444706 | 0.77 | TRPV4 (0.38) | CCR2MAPTNOS1NOS2TACR1 | |
| SCHEMBL10104415 | 0.76 | TACR1 (0.45) | CCR2NOS1NOS2TACR1NOS3 | |
| SCHEMBL12626853 | 0.73 | CYP3A4 (0.32) | TACR1 | |
| SCHEMBL10169147 | 0.73 | NOS1 (0.44) | NOS1NOS2TACR1NOS3 | |
| SCHEMBL798902 | 0.71 | PPARG (0.36) | MAPTNOS1NOS3GRIN2B | |
| SCHEMBL10494294 | 0.71 | GLA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318656-B2 | Production processes and systems, compositions, surfactants, monomer units, metal complexes, phosphate esters, glycols, aqueous film forming foams, and foam stabilizers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120071689-A1 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | E.I. DU PONT DE NEMOURS AND COMPANY CHEMTURA CORPORATION (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071689-A1 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | FOS, AFF4, AFF1 | CCR2 4552/4885MAPT 189/4885NOS1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.